Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123285
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:42
Documents
78
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnth-20240930.htm   iXBRL 10-Q 2030265
2 EX-31.1 dnth-ex31_1.htm EX-31.1 17197
3 EX-31.2 dnth-ex31_2.htm EX-31.2 17270
4 EX-32.1 dnth-ex32_1.htm EX-32.1 15168
  Complete submission text file 0000950170-24-123285.txt   9185309

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20240930.xsd EX-101.SCH 1440810
80 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20240930_htm.xml XML 1618671
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38541 | Film No.: 241435530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)